97 related articles for article (PubMed ID: 8042618)
1. Inhibition by aurintricarboxylic acid of von Willebrand factor binding to platelet GPIb, platelet retention, and thrombus formation in vivo.
Kawasaki T; Kaku S; Kohinata T; Sakai Y; Taniuchi Y; Kawamura K; Yano S; Takenaka T; Fujimura Y
Am J Hematol; 1994 Sep; 47(1):6-15. PubMed ID: 8042618
[TBL] [Abstract][Full Text] [Related]
2. The antithrombotic effect of aurin tricarboxylic acid in the guinea pig is not solely due to its interaction with the von Willebrand factor-GPIb axis.
Azzam K; Cissé-Thiam M; Drouet L
Thromb Haemost; 1996 Jan; 75(1):203-10. PubMed ID: 8713802
[TBL] [Abstract][Full Text] [Related]
3. Aurin tricarboxylic acid inhibits platelet adhesion to collagen by binding to the 509-695 disulphide loop of von Willebrand factor and competing with glycoprotein Ib.
Girma JP; Fressinaud E; Christophe O; Rouault C; Obert B; Takahashi Y; Meyer D
Thromb Haemost; 1992 Dec; 68(6):707-13. PubMed ID: 1287886
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of the antithrombotic effect of aurintricarboxylic acid on arterial thrombosis in rats and guinea pigs.
Takiguchi Y; Shimazawa M; Nakashima M
Br J Pharmacol; 1996 Aug; 118(7):1633-8. PubMed ID: 8842425
[TBL] [Abstract][Full Text] [Related]
5. Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis.
Lei X; Reheman A; Hou Y; Zhou H; Wang Y; Marshall AH; Liang C; Dai X; Li BX; Vanhoorelbeke K; Ni H
Thromb Haemost; 2014 Feb; 111(2):279-89. PubMed ID: 24172860
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of von Willebrand factor binding to platelet GP Ib by a fractionated aurintricarboxylic acid prevents restenosis after vascular injury in hamster carotid artery.
Matsuno H; Kozawa O; Niwa M; Uematsu T
Circulation; 1997 Aug; 96(4):1299-304. PubMed ID: 9286962
[TBL] [Abstract][Full Text] [Related]
7. Aurin tricarboxylic acid: a novel inhibitor of the association of von Willebrand factor and platelets.
Phillips MD; Moake JL; Nolasco L; Turner N
Blood; 1988 Dec; 72(6):1898-903. PubMed ID: 3264193
[TBL] [Abstract][Full Text] [Related]
8. Isolation from commercial aurintricarboxylic acid of the most effective polymeric inhibitors of von Willebrand factor interaction with platelet glycoprotein Ib. Comparison with other polyanionic and polyaromatic polymers.
Weinstein M; Vosburgh E; Phillips M; Turner N; Chute-Rose L; Moake J
Blood; 1991 Nov; 78(9):2291-8. PubMed ID: 1932745
[TBL] [Abstract][Full Text] [Related]
9. Multiple inhibition of platelet activation by aurintricarboxylic acid prevents vascular stenosis after endothelial injury in hamster carotid artery.
Matsuno H; Kozawa O; Niwa M; Tanabe K; Ichimaru K; Takiguchi Y; Yokota M; Hayashi H; Uematsu T
Thromb Haemost; 1998 Apr; 79(4):865-71. PubMed ID: 9569206
[TBL] [Abstract][Full Text] [Related]
10. Enhanced botrocetin-induced type IIB von Willebrand factor binding to platelet glycoprotein Ib initiates hyperagglutination of normal platelets.
Nishio K; Fujimura Y; Niinomi K; Takahashi Y; Yoshioka A; Fukui H; Usami Y; Titani K; Ruggeri ZM; Zimmerman TS
Am J Hematol; 1990 Apr; 33(4):261-6. PubMed ID: 2316510
[TBL] [Abstract][Full Text] [Related]
11. Echicetin: a snake venom protein that inhibits binding of von Willebrand factor and alboaggregins to platelet glycoprotein Ib.
Peng M; Lu W; Beviglia L; Niewiarowski S; Kirby EP
Blood; 1993 May; 81(9):2321-8. PubMed ID: 8481512
[TBL] [Abstract][Full Text] [Related]
12. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor.
Kageyama S; Yamamoto H; Nagano M; Arisaka H; Kayahara T; Yoshimoto R
Br J Pharmacol; 1997 Sep; 122(1):165-71. PubMed ID: 9298543
[TBL] [Abstract][Full Text] [Related]
13. Aurintricarboxylic acid in a canine model of coronary artery thrombosis.
Strony J; Phillips M; Brands D; Moake J; Adelman B
Circulation; 1990 Mar; 81(3):1106-14. PubMed ID: 2306818
[TBL] [Abstract][Full Text] [Related]
14. Platelet-vessel wall interactions in thrombosis and restenosis role of von Willebrand factor.
Hoylaerts MF
Verh K Acad Geneeskd Belg; 1997; 59(3):161-83. PubMed ID: 9490916
[TBL] [Abstract][Full Text] [Related]
15. Ristocetin and botrocetin involve two distinct domains of von Willebrand factor for binding to platelet membrane glycoprotein Ib.
Girma JP; Takahashi Y; Yoshioka A; Diaz J; Meyer D
Thromb Haemost; 1990 Oct; 64(2):326-32. PubMed ID: 1702906
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms of glycoprotein Ib affect the inhibition by aurintricarboxylic acid of the von Willebrand factor dependent platelet aggregation.
Boncler MA; Golanski J; Paczuski R; Watala C
J Mol Med (Berl); 2002 Dec; 80(12):796-801. PubMed ID: 12483465
[TBL] [Abstract][Full Text] [Related]
17. The interaction between components of the fibrinolytic system and GPIb/V/IX of platelets thrombus formation in mice.
Matsuno H; Kozawa O; Ueshima S; Matsuo O; Collen D; Uematsu T
Br J Pharmacol; 2000 Oct; 131(4):858-64. PubMed ID: 11030738
[TBL] [Abstract][Full Text] [Related]
18. The chimeric monoclonal antibody MHCSZ-123 against human von Willebrand factor A3 domain inhibits high-shear arterial thrombosis in a Rhesus monkey model.
Ji S; Jiang M; Yan B; Shen F; He Y; Wan A; Xia L; Ruan C; Zhao Y
J Hematol Oncol; 2017 May; 10(1):111. PubMed ID: 28526067
[TBL] [Abstract][Full Text] [Related]
19. N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
Lanke E; Kristoffersson AC; Isaksson C; Holmberg L; Lethagen S
Eur J Haematol; 2008 Nov; 81(5):384-90. PubMed ID: 18637125
[TBL] [Abstract][Full Text] [Related]
20. Alboaggregin-B and botrocetin, two snake venom proteins with highly homologous amino acid sequences but totally distinct functions on von Willebrand factor binding to platelets.
Yoshida E; Fujimura Y; Miura S; Sugimoto M; Fukui H; Narita N; Usami Y; Suzuki M; Titani K
Biochem Biophys Res Commun; 1993 Mar; 191(3):1386-92. PubMed ID: 8466514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
